Food Allergy Market Set to Undergo Transformative Growth by 2034 - DelveInsight | Aimmune Therapeutics, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma, COUR Pharmaceuticals

Food allergy is poised for major transformation, driven by strong epidemiological insights and advanced forecasting across the 7MM (the US, EU4, the UK, and Japan). The rise of next-gen therapies from innovators like Aimmune Therapeutics, Novartis, DBV Technologies, Regeneron, Genentech, and Alladapt Immunotherapeutics marks a shift toward proactive diagnosis, long-term tolerance, and better outcomes.
DelveInsight's latest report, "Food Allergy Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]," provides a comprehensive analysis of the current and future landscape of the food allergy market. The report offers in-depth epidemiological trends, market dynamics, and emerging treatment approaches, empowering stakeholders with the insights needed to navigate evolving challenges and seize upcoming opportunities in this rapidly advancing field. With increasing awareness, research breakthroughs, and a strong pipeline, the food allergy market is poised for exponential growth through 2034.

Some of the key insights of the Food Allergy Market Report:

- The Food Allergy market size was valued at USD 1.6 billion in 2023 and is expected to grow significantly by the end of 2034, with a CAGR during the forecast period (2024-2034).

- DelveInsight estimates that approximately 57 million prevalent cases of Food Allergy were found in 2023 across the 7MM.

- In the US, the total prevalent cases of Food Allergy were around 33 million in 2023, with projections for an increase during the forecast period due to rising awareness among the patient population and the launch of novel therapies.

- The total prevalent cases of Food Allergy in the EU4 and the UK were approximately 17 million in 2023.

- The total prevalent cases of Food Allergy in Japan were estimated to be around 7.4 million in 2023, with a projected decrease by 2034.

- In March 2025, Celltrion announced that the FDA approved OMLYCLO (omalizumab-igec) as the first interchangeable biosimilar to XOLAIR (omalizumab) for treating moderate to severe asthma, CRSwNP, IgE-mediated food allergies, and CSU.

- Emerging therapies for Food Allergy include Ligelizumab, Viaskin Peanut, and others.

- Key companies involved in the treatment of Food Allergy include Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.

To know in detail about the Food Allergy market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Food Allergy Market Forecast Report [https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Food Allergy Overview

A food allergy is a serious and potentially life-threatening immune-mediated response that occurs consistently upon exposure to a specific food allergen. It results from the immune system mistakenly identifying certain proteins in food as harmful invaders. These proteins-commonly found in foods like peanuts, shellfish, eggs, milk, and wheat-are known as food allergens. When a person with a food allergy consumes or comes into contact with even trace amounts of the allergenic food, their immune cells (particularly IgE antibodies) recognize the allergen and trigger a cascade of immune reactions. This response leads to the release of histamines and other inflammatory mediators, causing a range of symptoms from mild (rash, itching, stomach cramps) to severe (anaphylaxis, difficulty breathing, or even loss of consciousness).

Food allergies can manifest at any age, but they are most common in children. Unlike food intolerances, which do not involve the immune system, true food allergies can have rapid and reproducible reactions-even at very low exposure levels-requiring strict avoidance and emergency preparedness. Early diagnosis, personalized management, and access to emerging therapies are essential for improving the quality of life and safety of individuals living with food allergies.

Get a free sample for the food allergy market forecast, size & share analysis report: https://www.delveinsight.com/report-store/food-allergy-market-insights [https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Food Allergy Epidemiology

The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Food Allergy Epidemiology Segmentation:

The food allergy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:

- Total Prevalent cases of Food Allergy

- Etiology-specific cases of Food Allergy

- Age-specific cases of Food Allergy

Food Allergy Drugs Uptake and Pipeline Development Activities

The drug uptake section examines the adoption rates of newly launched and upcoming Food Allergy drugs over the study period. It analyzes the uptake of these treatments, evaluating how patients adopt these therapies and the sales performance of each drug. This section provides a comprehensive overview of the factors that influence the acceptance and success of Food Allergy treatments on the market.

In addition, the therapeutics assessment section highlights the Food Allergy drugs that have experienced the fastest uptake. It delves into the key drivers behind their widespread use and provides a comparison of market share among these drugs. This section helps identify which therapies are gaining traction and the reasons behind their rapid adoption.

The report further explores the Food Allergy pipeline, providing insights into therapeutic candidates at different stages of development. It identifies the key companies involved in creating targeted Food Allergy treatments. The report also covers recent developments in the field, including collaborations, mergers, acquisitions, licensing agreements, and other significant updates on emerging therapies for Food Allergy.

Explore how emerging therapies are aligning with evolving patient populations - download the report [https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] to uncover key drivers shaping the Food Allergy pipeline and epidemiology trends.

Food Allergy Market Outlook

The treatment landscape for food allergies is varied, with key therapies including Epinephrine, Anti-histamines, Steroids, Beta-2-agonists, and Palforzia as needed for management. Among these, Palforzia stands out as a significant revenue contributor in the current market.

The food allergy market is poised for strong growth, driven by the anticipated approval of promising therapies such as Ligelizumab (Novartis Pharmaceuticals) and Viaskin Peanut (DBV Technologies), among others.

In 2023, the total market size for food allergies across the 7MM was approximately USD 1.6 billion, with projections indicating robust expansion throughout the forecast period.

Food Allergy Market Drivers

- The rising incidence of food allergies, especially in children, is driving demand for innovative therapies and treatments.

- Ongoing research into food allergy immunotherapies offers new treatment options, fostering growth in the food allergy market.

Food Allergy Market Barriers

- Despite growing awareness, there are limited treatment options that offer long-term relief or a cure for food allergies.

- The cost of food allergy treatments and therapies, including immunotherapy and epinephrine injectors, can be prohibitive for many patients, limiting market growth.

Scope of the Food Allergy Market Report

- Study Period: 2020-2034

- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

- Key Food Allergy Companies: Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.

- Key Food Allergy Therapies: Ligelizumab, Viaskin Peanut, and others.

- Food Allergy Therapeutic Assessment: Food Allergy currently marketed, and Food Allergy emerging therapies

- Food Allergy Market Dynamics: Food Allergy market drivers and Food Allergy market barriers

- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

- Food Allergy Unmet Needs, KOL's views, Analyst's views, Food Allergy Market Access and Reimbursement

To learn more about Food Allergy companies working in the treatment market, visit @ Food Allergy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Table of Contents

1. Food Allergy Market Report Introduction

2. Executive Summary for Food Allergy

3. SWOT analysis of Food Allergy

4. Food Allergy Patient Share (%) Overview at a Glance

5. Food Allergy Market Overview at a Glance

6. Food Allergy Disease Background and Overview

7. Food Allergy Epidemiology and Patient Population

8. Country-Specific Patient Population of Food Allergy

9. Food Allergy Current Treatment and Medical Practices

10. Food Allergy Unmet Needs

11. Food Allergy Emerging Therapies

12. Food Allergy Market Outlook

13. Country-Wise Food Allergy Market Analysis (2020-2034)

14. Food Allergy Market Access and Reimbursement of Therapies

15. Food Allergy Market Drivers

16. Food Allergy Market Barriers

17. Food Allergy Appendix

18. Food Allergy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=food-allergy-market-set-to-undergo-transformative-growth-by-2034-delveinsight-aimmune-therapeutics-novartis-pharmaceuticals-dbv-technologies-innoup-farma-cour-pharmaceuticals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.